|
Market Closed -
Börse Stuttgart
23:46:14 04/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 129.48 EUR | -0.43% |
|
+1.90% | +22.93% |
| 09-03 | AbbVie's blood cancer therapy lowers disease progression, death risk in trial | RE |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 187,227 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 22.95% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 203,972 | 196,352 | 190,062 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 20.28% | -3.74% | -3.2% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -46.1x | 18.8x | 17.3x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 10.3x | 7.8x | 6.22x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.03x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.1x | 5.73x | 5.45x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.65x | 6.01x | 5.53x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 26x | 11x | 10.4x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 63.2x | 12.4x | 11.3x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -387x | 15x | 13.7x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.26% | 6.66% | 7.3% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.296 | 3.396 | 3.102 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.18% | 2.25% | 2.05% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.273 | 8.021 | 8.705 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -101% | 42.3% | 35.6% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,688 | 32,679 | 34,344 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,859 | 17,834 | 18,324 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,226 | 15,830 | 16,887 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,275 | 10,275 | 10,917 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 16,745 | 9,125 | 2,835 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 151.00 | 151.00 | 151.00 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 01/02/22 | 02/02/23 | 06/02/24 | 11/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.72x | 11.9x | 24.26x | 0.6% | 1,024B | |
| 30.62x | - | - | 1.95% | 663B | |
| 32.73x | 7.6x | 15.8x | 2.67% | 453B | |
| 19.89x | 4.73x | 11.71x | 2.8% | 352B | |
| 22.72x | 5.84x | 14.51x | 2.7% | 304B | |
| 20.87x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.66x | 7.14x | 13.15x | 2.31% | 236B | |
| 13.33x | 4.82x | 10.06x | 3.78% | 206B | |
| -46.14x | 6.65x | 25.95x | 2.18% | 187B | |
| Average | 17.16x | 6.62x | 15.96x | 2.34% | 408.71B | |
| Weighted average by Cap. | 24.05x | 7.99x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- GIS Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
